Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
Children/adolescents with attention-deficit/hyperactivity disorder (ADHD) may have a poor or inadequate response to psychostimulants or be unable to tolerate their side-effects; furthermore, stimulants may be inappropriate because of co-existing conditions. Only one non-stimulant ADHD pharmacotherapy, the noradrenaline transporter inhibitor atomoxetine, is currently approved for use in Europe. We review recent advances in understanding of the pathophysiology of ADHD with a focus on the roles of catecholamine receptors in context of the α2A-adrenergic receptor agonist guanfacine extended release (GXR), a new non-stimulant treatment option in Europe. Neuroimaging studies of children/adolescents with ADHD show impaired brain maturation, and structural and functional anomalies in brain regions and networks. Neurobiological studies in ADHD and medication response patterns support involvement of monoaminergic neurotransmitters (primarily dopamine and noradrenaline). Guanfacine is a selective α2A-adrenergic receptor agonist that has been shown to improve prefrontal cortical cognitive function, including working memory. The hypothesized mode of action of guanfacine centres on direct stimulation of post-synaptic α2A-adrenergic receptors to enhance noradrenaline neurotransmission. Preclinical data suggest that guanfacine also influences dendritic spine growth and maturation. Clinical trials have demonstrated the efficacy of GXR in ADHD, and it is approved as monotherapy or adjunctive therapy to stimulants in Canada and the USA (for children and adolescents). GXR was approved recently in Europe for the treatment of ADHD in children and adolescents for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. GXR may provide particular benefit for children/adolescents who have specific co-morbidities such as chronic tic disorders or oppositional defiant disorder (or oppositional symptoms) that have failed to respond to first-line treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The worldwide prevalence of ADHD: a systematic review and metaregression analysis
Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman, J., & Rohde, L. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.942 · Cited by 5,346
(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1073 · Cited by 3,372
Stress signalling pathways that impair prefrontal cortex structure and function
Arnsten, A. F. T. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2648 · Cited by 3,299
Blockade of NMDA Receptors and Apoptotic Neurodegeneration in the Developing Brain
Ikonomidou, C., Bosch, F., Miksa, M., Bittigau, P., Vöckler, J., Dikranian, K., Tenkova, T. I., Stefovska, V., Turski, L., & Olney, J. W. (1999) · Science · doi:10.1126/science.283.5398.70 · Cited by 2,055
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
Castellanos, F. X. (2002) · JAMA · doi:10.1001/jama.288.14.1740 · Cited by 1,646
Emotion Dysregulation in Attention Deficit Hyperactivity Disorder
Shaw, P., Stringaris, A., Nigg, J., & Leibenluft, E. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070966 · Cited by 1,232
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
Toward systems neuroscience of ADHD: a meta-analysis of 55 fMRI studies
Cortese, S., Kelly, C., Chabernaud, C., Proal, E., Di Martino, A., Milham, M. P., & Castellanos, F. X. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.11101521 · Cited by 1,067 · cited 7×
“Resting-state fMRI data have shown dysfunctional con- nectivity in the DMN in affected children/adolescents and adults versus controls, which supports the hypothesis that ADHD is related to delayed or disrupted maturation of the DMN [31, 32, 35, 48–50].”
BackgroundInfluentialCandidate gene studies of ADHD: a meta-analytic review
Gizer, I. R., Ficks, C., & Waldman, I. D. (2009) · Human Genetics · doi:10.1007/s00439-009-0694-x · Cited by 1,020
Cited by
Updated European Consensus Statement on diagnosis and treatment of adult ADHD
Kooij, J. J. S., Bijlenga, D., Salerno, L., Jaeschke, R., Bitter, I., Balázs, J., Thome, J., Dom, G., Kasper, S., Nunes Filipe, C., et al. (2019) · European Psychiatry · doi:10.1016/j.eurpsy.2018.11.001 · Cited by 686
“In Europe, guanfacine extended-release (GXR), an alfa-2 adrenergic agonist, is licensed for the treatment of children and adolescents with ADHD for whom stimulants are not suitable, not tolerated or where shown to be ineffective [256,257].”
BackgroundEvidence-based pharmacological treatment options for ADHD in children and adolescents
Mechler, K., Banaschewski, T., Hohmann, S., & Häge, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107940 · Cited by 293
Johnson, J. K., Liranso, T., Saylor, K., Tulloch, G., Adewole, T., Schwabe, S., Nasser, A., Findling, R. L., & Newcorn, J. H. (2020) · Journal of Attention Disorders · doi:10.1177/1087054719836159 · Cited by 62
Garcia-Argibay, M., Li, L., Du Rietz, E., Zhang, L., Yao, H., Jendle, J., Ramos-Quiroga, J. A., Ribasés, M., Chang, Z., Brikell, I., et al. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105076 · Cited by 52
“…during the follow-up period (methylphenidate: N06BA04, amphetamine: N06BA01, dexamphetamine: N06BA02, atomoxetine: N06BA09, lisdexamfetamine: N06BA12) from the PDR. Guanfacine (C02AC02) was not included as, in Sweden, it was not approved for the treatment of ADHD until 2016 (Huss et al., 2016).”
Iwanami, A., Saito, K., Fujiwara, M., Okutsu, D., & Ichikawa, H. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12979 · Cited by 44
Metadata
- Authors
- Huss, M., Chen, W., & Ludolph, A. G.
- Venue
- Clinical Drug Investigation
- Published
- 2015-11-20
- Volume
- 36
- Issue
- 1
- Pages
- 1-25
- ISSN
- 0114-2402 (ISSN-L)
- 1173-2563
- 1179-1918
- OpenAlex
- W2179646396
- Cited by
- 56
- References
- 95
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe. https://app.cochat.ai/papers/10.1007/s40261-015-0336-0
- The paper
- Huss, M., Chen, W., & Ludolph, A. G. (2016). Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe. Clinical Drug Investigation. https://doi.org/10.1007/s40261-015-0336-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.